Combination treatments for melanoma
US9561245B2 · kind B2 · utility
0Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 5, 2013 |
| Grant date | Feb 7, 2017 |
| Priority date | — |
| Expiry date | Apr 23, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/585
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.